Panchkula-based pharma manufacturer of critical-care injectables & generics, sold in 90+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 12 | 12 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 311 | 388 | 427 | 447 | 474 | 548 | 581 | 650 |
| Borrowings | 220 | 51 | 43 | 42 | 41 | 2 | 14 | 12 |
| Other Liabilities | 100 | 104 | 97 | 98 | 98 | 153 | 159 | 178 |
| Total Liabilities | 644 | 556 | 580 | 601 | 627 | 716 | 768 | 854 |
| AssetsFixed Assets | 289 | 262 | 241 | 216 | 219 | 229 | 237 | 232 |
| CWIP | 25 | 25 | 25 | 26 | 21 | 26 | 34 | 51 |
| Investments | 0 | 0 | 0 | 20 | 19 | 84 | 193 | 238 |
| Other Assets | 330 | 269 | 314 | 339 | 368 | 376 | 303 | 333 |
| Total Assets | 644 | 556 | 580 | 601 | 627 | 716 | 768 | 854 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Cash from Investing | -11 | -5 | 57 | -17 | -58 | -8 | -77 | -182 |
| Cash from Financing | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 35 | 70 | 132 | 41 | 29 | 24 | 69 | 118 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
VENUSREM · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.